FASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
3.Chen R, et al. Efficacy and safety of mepolizumab as an add-on therapy in Chinese patients with severe eosinophilic asthma: a randomized, double-blind, parallel group Phase 3 study. Am J Respir Crit Care Med. 2023;207:A4766. 4.Nagasaki T, et al. The prevalence and disease burden of...
AstraZeneca近日宣布,其创新药物Fasenra(通用名:benralizumab)已经获得美国食品和药物管理局(FDA)的扩展批准,可用于6至11岁患有严重嗜酸粒细胞性哮喘(Severe Eosinophilic Asthma,SEA)的儿科患者作为附加维持治疗。 这项新的适应症批准是基于开放标签的3期临床试验TATE的结果,以及先前在成人和青少年患者中进行的良好对照...
Fasenra should not be given for eosinophilic asthma to a child younger than 6 years old or for EGPA to an adolescent or child under the age of 18. Fasenra is not a rescue medicine for asthma attacks. Use only fast-acting inhalation medicine for an attack. Seek medical attention if your ...
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
with other asthma medicines for the maintenance treatment of asthma in people 6 years and older whose asthma is not controlled with their current asthma medicines. FASENRA is not used to treat sudden breathing problems. to treat people 18 years and older with eosinophilic granulomatosis with polyangi...
“Expanding options for children whose quality of life has been drastically impacted by severe eosinophilic asthma with the help of FASENRA is an exciting step in our mission to revolutionise asthma care.” Last month, the Japanese Ministry of Health, Labour and Welfare approved AstraZeneca’sTruq...
Fasenra (benralizumab) injection is an interleukin-5 receptor alpha-directed cytolyticmonoclonal antibody(IgG1, kappa) indicated for the add-on maintenance treatment of patients with severeasthmaaged 12 years and older, and with an eosinophilic phenotype. ...
NICE said Fasenra is an option for treating severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids and long-acting beta agonists - but only if patiens meet certain criteria. Patients must have had a high count of cells...